AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
AbbVie filed an sBLA for SKYRIZI as a subcutaneous induction therapy for Crohn's disease, supported by Phase 3 AFFIRM data. SKYRIZI and Rinvoq combined for $25.9B in 2025 revenue, exceeding 2027 guidance. The FDA also approved Venclexta plus acalabrutinib in CLL.
AbbVie reported positive Phase 3 data for Skyrizi's subcutaneous Crohn's disease treatment and is advancing lutikizumab and Rinvoq in hidradenitis suppurativa, with multiple readouts expected throughout 2026 as the company pursues combination therapy strategies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06972446 |
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis |
RECRUITING | PHASE2 |
| NCT06718101 |
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06548542 |
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease |
RECRUITING | PHASE2 |
| NCT06468228 |
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa |
ACTIVE_NOT_RECRUITING | PHASE3 |
